Cytogenetic risk assessment of etoposide from mouse bone marrow

Journal of Applied Toxicology

Volumn 24, Issue 2, 2004, Pages 115-122

  Choudhury, Ramesh C ^a   Palo, Anil K ^a   Sahu, Prajyoti ^a  

^a BERHAMPUR UNIVERSITY   (India)

Author keywords

Bone marrow; Chromosome aberration; Cytogenetic toxicity; Etoposide; Micronucleus; Mitotic index; Swiss mice; Topoisomerase II inhibitor

Indexed keywords

ACETIC ACID; ANTINEOPLASTIC AGENT; CITRATE SODIUM; COLCHICINE; CYCLOPHOSPHAMIDE; DNA; DNA TOPOISOMERASE (ATP HYDROLYSING); EPIPODOPHYLLOTOXIN DERIVATIVE; ETOPOSIDE; FYTOSID; HYPOTONIC SOLUTION; INTERCALATING AGENT; METHANOL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW TOXICITY; CANCER CELL; CANCER SURVIVAL; CELL CYCLE; CELL DIVISION; CELL PROLIFERATION; CHROMOSOME ABERRATION; CONTROLLED STUDY; CYTOGENETICS; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG EXPOSURE; DRUG SPECIFICITY; DRUG TARGETING; ENZYME ACTIVITY; FEMALE; GENOTOXICITY; GIEMSA STAIN; IN VIVO STUDY; LEUKEMOGENESIS; LOW DRUG DOSE; MALE; METAPHASE; MICRONUCLEUS TEST; MITOSIS INDEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BONE MARROW CELLS; CHROMOSOME ABERRATIONS; CYTOGENETIC ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; ETOPOSIDE; FEMALE; INJECTIONS, INTRAPERITONEAL; MALE; MICE; MICRONUCLEUS TESTS; MITOTIC INDEX; MUTAGENS; RISK ASSESSMENT;

EID: 1842666763     PISSN: 0260437X     EISSN: None     Source Type: Journal    
DOI: 10.1002/jat.959     Document Type: Article

References (72)

1. Agarwal K, Mukherjee A, Sen S. 1994. Etoposide (VP-16): cytogenetic studies in mice. Environ. Mol. Mutagen. 23: 190-193.
2. Andersen AH, Christiansen K, Zechiedrich EL, Jensen PS, Osheroff N, Westergaard O. 1989. Strand specificity of the topoisomerase II mediated double-stranded DNA cleavage reaction. Biochemistry 28: 6237-6244.
3. Anderson RD, Berger NA. 1994. Mutagenicity and carcinogenicity of topoisomerase-interactive agents. Mutat. Res. 309: 109-142.
4. Anderson D, Bishop JB, Garner RC, Otrosky-Wegman P, Selby PB. 1995. Cyclophosphamide: review of its mutagenicity for an assessment of potential germ cell risks. Mutat. Res. 330: 115-182.
5. Ashby J, Tinwell H, Glover P, Poorman-Allen P, Krehl R, Callander RD, Clive D. 1994. Potent clastogenicity of the human carcinogen etoposide to the mouse bone marrow and mouse lymphoma L5178Y cells: comparison to Salmonella responses. Environ, Mol. Mutagen. 24: 51-60.
6. Berger NA, Chatterjee S, Schmotzer JA, Helms SR. 1991. Etoposide (VP16-213)-induced gene alterations: potential contribution to cell death. Proc. Natl. Acad. Sci. USA 88: 8740-8743.
7. Bishop JF. 1999. Principles of chemotherapy. In Cancer Facts-A Concise Oncology Text, Bishop JF (ed.). Harwood Academic Publishers: Australia; 46-51.
8. Blagosklonny MV. 2002. p53: a ubiquitous target of anticancer drugs. Int. J. Cancer 98: 161-166.
9. Caporossi D, Porfirio B, Nicoletti B, Palitti F, Degrassi F, De Salvia R, Tanzarella C. 1993. Hypersensitivity of lymphoblastoid lines derived from ataxia telangiectasia patients to the induction of chromosomal aberrations by etoposide (VP-16). Mutat. Res. 290: 265-272.
10. Chabner BA, Allegra CJ, Curt GA, Calabresi P. 1996. Antineoplastic agents. In Goodman and Gilman's The Pharmacological Basis of Therapeutics, Hardman JG et al. (eds). McGraw Hill: New York; 1233-1285.
11. Chatterjee S, Trivedi D, Petzold SJ, Berger NA. 1990. Mechanism of epipodophyllotoxin-induced cell death in poly (adenosine diphosphate-ribose) synthesis-deficient V79 Chinese hamster cell lines. Cancer Res. 50: 2713-2718.
12. Chen GL, Yang L, Rowe TC, Halligan BD, Tewey KM, Liu LF. 1984. Nonintercalative anticancer drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerases II. J. Biol. Chem. 259: 13560-13566.
13. Choudhury RC, Hasan A, Mahanty V. 1995. Effects of mercuric chloride on mitotic, meiotic chromosomes and sperm in mice. Biol. Zent. Bl. 114: 369-377.
14. Choudhury RC, Jagdale MB, Misra S. 2000. Cytogenetic toxicity of cisplatin in bone marrow cells of Swiss mice. J. Chemother. 12: 173-182.
15. Curtis RE, Boice Jr JD, Moloney WC, Ries LG, Flannery JT. 1990. Leukaemia following chemotherapy for breast cancer. Cancer Res. 50: 2741-2746.
16. de Serres FJ, Matsushima T. 1986. Meeting Report: mutagenesis and carcinogenesis by nitropyrenes and chemotherapeutics. Mutat. Res. 164: 3-8.
17. Downes CS, Mullinger AM, Johnson RT. 1991. Inhibitors of DNA topoisomerase II prevent chromatid separation in mammalian cells but do not prevent exit from mitosis. Proc. Natl. Acad. Sci. USA 88: 8895-8899.
18. Ferguson LR. 1995. Mutagenic properties of anticancer drugs. In The Genetics of Cancer, Ponder BAJ, Waring MJ (eds). Kluwer Scientific Publishers: Lancaster; 177-216.
19. Ferguson LR, Baguley BC. 1994. Topoisomerase II enzymes and mutagenicity. Environ. Mol. Mutagen. 24: 245-261.
20. Ferguson LR, Denny WA. 1995. Anticancer drugs an underestimated risk or an underutilized resource in mutagenesis? Mutat. Res. 331: 1-26.
21. Ferguson LR, Pearson AE. 1996. The clinical use of mutagenic anticancer drugs. Mutat. Res, 335: 1-12.
22. Fucic A, Jazbec A, Mijic A, Seso-Simic D, Tomek R. 1998. Cytogenetic consequences after occupational exposure to antineoplastic drugs. Mutat. Res. 416: 59-66.
23. Gupta R. 1990. Tests for the genotoxicity of m-AMSA, etoposide, teniposide and ellipticine in Neurospora crassa. Mutat. Res. 240: 47-58.
24. Gupta RS, Bromke A, Bryant DW, Gupta R, Singh B, McCalla DR. 1987. Etoposide (VP16) and teniposide (VM26): novel anticancer drugs, strongly mutagenic in mammalian but not prokaryotic test systems. Mutagenesis 2: 179-186.
25. Huang CC, Hou Y, Wang JJ. 1973. Effects of new antitumour agent epipodophyllotoxin, on growth and chromosomes in human haematopoietic cell lines. Cancer Res. 33: 3123-3129.
26. Jackson MA, Stack HF, Waters MD. 1996. Genetic activity profiles of anticancer drugs. Mutat. Res. 355: 171-208.
27. Jeggo PA, Caldecott K, Pidsley S, Banks GR. 1989. Sensitivity of Chinese hamster ovary mutants defective in DNA double strand break repair to topoisomerase II inhibitors. Cancer Res. 49: 7057-7063.
28. Kallio M, Lahdetie J. 1993. Analysis of micronuclei induced in mouse early spermatids by mitomycin C, vinblastine sulphate or etoposide using fluorescence in situ hybridisation (FISH). Mutagenesis 8: 561-567.
29. Kastenbaum MA, Bowman KO. 1970. Tables for determining the statistical significance of mutation frequencies. Mutat. Res. 9: 529-549.
30. Kerrigan D, Pommier Y, Kohn KW. 1987. Protein-linked DNA strand breaks produced by etoposide and teniposide in mouse L1210 and human VA-13 and HT-29 cell lines: relationship to cytotoxicity. J. Natl. Cancer Inst. Monogr. 4: 117-121.
31. Krishna G, Petrere J, Anderson J, Theiss J. 1995. Use of cyclophosphamide as a positive control in dominant lethal and mammalian assays. Mutat. Res. 335: 331-337.
32. Lahdetie J, Keiski A, Suutari A, Toppari J. 1994. Etoposide (VP-16) is a potent inducer of micronuclei in male rat meiosis: spermatid micronucleus test and DNA flow cytometry after etoposide treatment. Environ. Mol. Mutagen. 24: 192-202.
33. Liu LF. 1989. DNA topoisomerase poisons as antitumor drugs. Annu. Rev. Biochem. 58: 351-375.
34. cdc2 kinase in etoposide induced cell death in Chinese hamster ovary cells. Cancer Res. 50: 3767-3771.
35. Long BH, Musial ST, Brattain MG. 1986. DNA breakage in human lung carcinoma cells and nuclei that are naturally sensitive or resistant to etoposide and teniposide. Cancer Res. 46: 3809-3816.
36. Machemer L, Lorke D. 1978. Mutagenicity studies with praziquantel, a new anthelmintic drug, in mammalian systems. Arch. Toxicol. 39: 187-197.
37. Maraschin J, Dutrillaux B, Aurias A. 1990. Chromosome aberrations induced by etoposide (VP-16) are not random. Int. J. Cancer 46: 808-812.
38. Marselos M, Vainio H. 1991. Carcinogenic properties of pharmaceutical agents evaluated in the IARC Monographs programme. Carcinogenesis 12: 1751-1766.
39. Matney TS, Nguyen TV, Connor TH, Dana WJ, Theiss JC. 1985. Genotoxic classification of anticancer drugs. Teratog. Carcinog. Mutag. 5: 319-328.
40. Mavournin KH, Blakey DH, Cimino MC, Salamone MF, Heddle JA. 1990. The in vivo micronucleus assay in mammalian bone marrow and peripheral blood. A report of the U.S. Environmental Protection Agency Gene-Tox program. Mutat. Res. 239: 29-80.
41. Mohn GR, Ellenberger J. 1976. Genetic effects of cyclophosphamide, ifosfamide and trafosfamide. Mutat. Res. 32: 331-360.
42. Murphy SB. 1993. Secondary acute myeloid leukaemia following treatment with epipodophyllotoxins. J. Clin. Oncol. 11: 199-201.
43. Nakanomyo H, Hiraoka M, Shiraya M. 1986. Mutagenicity test of etoposide and teniposide. J. Toxicol. Sci. 11: 301-310.
44. Nichols CR, Breeden ES, Loehrer PJ, Williams SD, Einhorn LH. 1993. Secondary leukaemia associated with a conventional dose of etoposide: review of serial germ cell tumour protocol. J. Natl. Cancer Inst. 85: 36-40.
45. Noda N, Wakasugi H. 2001. Cancer and oxidative stress. J. Med. Assoc. Jpn. 44: 535-539.
46. Osheroff N. 1989. Effect of antineoplastic agents on the DNA cleavage/religation reaction of eukaryotic topoisomerase II: inhibition of DNA religation by etoposide. Biochemistry 28: 6157-6160.
47. Palitti F. 1993. Mechanism of induction of chromosomal aberrations by inhibitors of DNA topoisomerases. Environ. Mol. Mutagen. 22: 275-277.
48. Palitti F, Degrassi F, De Salvia R, Tanzarella C. 1989. Inhibitors of DNA topoisomerases and chromosome aberrations. In Chromosomal Aberrations: Basic and Applied Aspects, Obe G, Natarajan AT (eds). Springer: Berlin; 50-60.
49. Pedersen-Bjergaard J, Philip P. 1987. Cytogenetic characteristics of therapy-related acute non-lymphocyte leukaemia, preleukaemia and acute myeloproliferative syndrome: correlation with clinical data for 61 consecutive cases. Br. J. Haematol. 66: 199-207.
50. Pinedo HM, Giaccone G. 1997. Chemotherapy. Lancet 349: 7-9.
51. Pommier Y, Kerrigan D, Covey JM, Kao-Shan C-S, Whang-Pang J. 1988. Sister chromatid exchanges, chromosomal aberrations, and cytotoxicity produced by antitumour topoisomerase II inhibitors in sensitive (DC3F) and resistant (DC3F/9-OHE) Chinese hamster cells. Cancer Res. 48: 512-516.
52. Pratt CB, Pui CH. 1991. Second tumours after treatment with anticancer drugs. In The Toxicity of Anticancer Drugs, Powis G, Hacker MP (eds). Pergamon Press: New York; 28-43.
53. Pui CH, Ribeiro RC, Hancock ML, Rivera GK, Evans WE, Raimondi SC, Head DR, Behm FG, Mahmoud MH, Sandlund JT. 1991. Acute myeloid leukaemia in children treated with epipodophyllotoxins for acute lymphoblastic leukaemia. N. Engl. J. Med. 325: 1682-1687.
54. Ratain MJ, Kaminer LS, Bitran JD, Larson RA, Le Beau MM, Skosey C, Purl S, Hoffman PC, Wade J, Vardiman JW, Daly K, Rowley JD, Golomb HM. 1987. Acute nonlymphocytic leukaemia following etoposide and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung. Blood 70: 1412-1417.
55. Rohrborn G, Basler A. 1977. Cytogenetic investigations of mammals. Comparison of the genetic activity of cytostatics in mammals. Arch. Toxicol. 38: 35-43.
56. Ross WE. 1985. DNA topoisomerases as targets for cancer therapy. Biochem. Pharmacol. 34: 4191-4195.
57. Ross WE, Rowe T, Glisson B, Yalowich J, Liu L. 1984. Role of topoisomerase II in mediating epipodophyllotoxin induced DNA cleavage. Cancer Res. 44: 5857-5860.
58. Sieber SM, Whang-Peng J, Botkin C, Knutsen T. 1978. Teratogenic and cytogenetic effects of some plant derived antitumour agents (vincristine, colchicine, maytansine, VP-16-213 and VM-26) in mice. Teratology 18: 31-48.
59. Singh B, Gupta RS. 1983. Mutagenic responses of thirteen anticancer drugs in mutation induction at multiple genetic loci and on sister chromatid exchanges in Chinese hamster ovary cells. Cancer Res. 43: 577-584.
60. Sinha BK, Haim N, Dusre L, Kerrigan D, Pommier Y. 1988. DNA strand breaks produced by etoposide (VP-16-213) in sensitive and resistant human breast tumour cells: implications for the mechanism of action. Cancer Res. 48: 5096-5100.
61. Sjoblom T, Parvinen M, Lahdetie J. 1994. Germ-cell mutagenicity of etoposide: induction of meiotic micronuclei in cultured rat seminiferous tubules. Mutat. Res. 323: 41-45.
62. Sladek NE. 1971. Metabolism of cyclophosphamide by rat hepatic microsomes. Cancer Res. 31: 901-908.
63. Sorsa M, Anderson D. 1996. Monitoring of occupational exposure to cytostatic anticancer agents. Mutat. Res. 355: 253-261.
64. Spiridonidis CA, Chatterjee S, Petzold SJ, Berger NA. 1989. Topoisomerase II-dependent and -independent mechanisms of etoposide resistance in Chinese hamster cell lines. Cancer Res. 49: 644-650.
65. Tominaga K, Shinkai T, Saijo N, Nakajima T, Ochi H, Suemasu K. 1986. Cytogenetic effects of etoposide (VP-16) on human lymphocytes with special reference to the relation between sister chromatid exchange and chromatid breakage. Jpn. J. Cancer Res. 77: 385-391.
66. Wang JC. 1985. DNA topoisomerases. Annu Rev Biochem 54: 665-697.
67. Weijl NI, Hopman GD, Wipkink-Bakker A, Lentjes EG, Berger HM, Cleton FJ, Osanto S. 1998. Cisplatin combination chemotherapy induces a fall in plasma antioxidants of cancer patients. Ann. Oncol. 9: 1331-1337.
68. Whitlock JA, Greer JP, Lukens JN. 1991. Epipodophyllotoxin-related leukaemia: identification of a new subset of secondary leukaemia. Cancer 68: 600-604.
69. Winick NJ, McKenna RW, Shuster JJ, Schneider NR, Borowitz MJ, Bowman WP. 1993. Secondary acute myeloid leukaemia in children with acute lymphoblastic leukaemia treated with etoposide. J. Clin. Oncol. 11: 209-217.
70. Wozniak AJ, Ross WE. 1983. DNA damage as a basis for 4′-demethylepipodophyllotoxin-9-(4,6-O-ethyiidene-β-D-glucopyranoside) (Etoposide) cytotoxicity. Cancer Res. 43: 120-124.
71. Yang L, Wold MS, Li JJ, Kelly TJ, Liu LF. 1987. Roles of DNA topoisomerases in simian virus 40 DNA replication in vitro. Proc. Natl. Acad. Sci. USA 84: 950-954.
72. Zechiedrich EL, Christiansen K, Andersen AH, Westergaard O, Osheroff N. 1989. Double-stranded DNA cleavage/religation reaction of eukaryotic topoisomerase II: evidence of a nicked DNA intermediate. Biochemistry 28: 6229-6236.